Clinical trials: Neoplasm, Brain
Adult Brain Tumors
Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with recurrent glioblastoma…
- Trial name
- NCT00387894
- Testing
- erlotinib hydrochloride
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Michael Prados
Metastatic, Cerebral Primitive Neuroectodermal Tumors
Treatment of High-Risk Cerebral Primitive Neuroectodermal Tumors in Children Aged Over 5 Years
Primary objective : To increase the 3 year progression-free survival from 40% to 60%. Patients included : metastatic, cerebral primitive neuroectodermal tumors in children aged over 5 years.
- Trial name
- NCT00936156
- Testing
- Chemotherapy (carboplatin, etoposide, thiotepa)
- Where
- France
- Volunteers
- 68 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Brain Tumor
FBY PET/CT in Patients With Brain Tumors
This study is an open-labeled phase II diagnostic clinical trial to explore the safety and clinical value of FBY in suspected adult brain tumor patients.
- Trial name
- NCT03980431
- Testing
- FBY PET Examination
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking Union Medical College Hospital
DMG, DIPG
Blood-Brain Barrier Disruption Using Exablate Magnetic Resonance-Guided Low Intensity Focused Ultrasound With Microbubbles in Combination With T-Cell Infusion in Patients With Newly Diagnosed Diffuse Midline Glioma (LIFT)
This is an open-label phase 1 safety and feasibility study evaluating a novel combination therapy for Diffuse Midline Glioma (DMG), an aggressive brain tumor with a very poor prognosis - an average one-year overall survival.
- Trial name
- LIFT (NCT07796061)
- Testing
- TAA-T Cell, BBB Disruption
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Children's National Research Institute
Breast Cancer, Brain Metastasis
Brain Metastasis Development Mechanism in BCBM Patients
This study is the experimental study for brain metastasis development mechanism in patients with breast cancer with brain metastasis
- Trial name
- NCT06330870
- Testing
- WGS/TME evaluation
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Samsung Medical Center
Glioma, CNS Tumor, Adult
Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors
This clinical trial is a 2-phase trial designed to evaluate the safety of tarlatamab in combination with a fixed dose of metronomic temozolomide in adolescents and adults with CNS tumors (stratified into two age-based cohorts)…
- Conditions
- Glioma, CNS Tumor, Adult, CNS Tumor, Childhood
- Trial name
- TARLATEM (NCT07243470)
- Testing
- Tarlatamab, Temozolomide (TMZ)
- Where
- 12 sites in France
- Volunteers
- 70 people
- Sponsor
- Centre Leon Berard
Leptomeningeal Neoplasm, Metastatic Lung Non-Small Cell Carcinoma
Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer
This phase I/Ib trial studies the side effects and best dose of CB-839 HCl when given together with sapanisertib in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced).
- Conditions
- Leptomeningeal Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Lung Non-Small Cell Carcinoma
- Trial name
- NCT04250545
- Testing
- Sapanisertib, Telaglenastat Hydrochloride
- Where
- 7 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Anovulation, FHA
FHA: Characterization of Metabolic Status, Brain Circuitry, and Stress-Reactivity
Functional Hypothalamic Amenorrhea (FHA), the spontaneous cessation of the menstrual cycle for at least 6 months after menstrual cyclicity has been established, is a common and reversible form of anovulation not due to…
- Conditions
- Anovulation, FHA, Eumenorrhea, Polycystic Ovary Syndrome
- Trial name
- NCT00453219
- Testing
- Screening evaluation, Meal Response, Blood Collection
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Emory University
Parkinson's Disease, Alzheimer's Disease
Biomarkers in Neural Disorders
This study seeks to establish the sensitivity and specificity of what appears to be a unique brainstem biomarker of Parkinson's Disease (PD) - an electrically induced olygosynaptic nasotrigeminal reflex response - in…
- Conditions
- Parkinson's Disease, Alzheimer's Disease, Progressive Supranuclear Palsy, Essential Tremor
- Trial name
- NCT02761707
- Testing
- Electrical Brainstem Responses, Olfactory Tests, Visual Deprivation
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Brain and Central Nervous System Tumors
Enzastaurin and Temozolomide in Treating Patients With Primary Gliomas
RATIONALE: Enzastaurin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00516607
- Testing
- enzastaurin hydrochloride, temozolomide, pharmacological study
- Where
- United Kingdom
- Volunteers
- 28 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Seriously Ill Patients, Cancer
Goals of Care Conversations Study
The long term goal is to improve quality of care in Veterans with serious illnesses by aligning medical care with Veterans' goals and values.
- Conditions
- Seriously Ill Patients, Cancer, Heart Failure, Interstitial Lung Disease
- Trial name
- LSTDI (NCT05001009)
- Testing
- Clinician Implementation Strategy Stage 1: low intensity clinician training, Clinician Implementation Strategy Stage 2: high intensity clinician training, Low patient engagement
- Where
- 3 sites in United States
- Volunteers
- 2,859 people
- Sponsor
- VA Office of Research and Development
Cognitive/Functional Effects, Metastatic Cancer
Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors
RATIONALE: Memantine may be able to decrease side effects caused by whole-brain radiation therapy. It is not yet known if memantine is effective in preventing side effects caused by whole-brain radiation therapy.
- Conditions
- Cognitive/Functional Effects, Metastatic Cancer, Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00566852
- Testing
- Memantine, Whole brain radiation therapy
- Where
- 235 sites in United States, Canada
- Volunteers
- 554 people
- Sponsor
- Radiation Therapy Oncology Group
Metastases, Neoplasm
Radiomics for Prediction of Long Term Survival and Local Failure After Stereotactic Radiotherapy for Brain Metastases
Published prognostic scores have limitations in prediction of long term survival after stereotactic radiotherapy for brain metastases. Moreover, no validated tools are available for prediction of local failure.
- Trial name
- NCT02265549
- Where
- Netherlands
- Volunteers
- 155 people
- Sponsor
- Maastricht Radiation Oncology
Brain Tumor
Cell Culture of Glioma Specimens for in Vitro Preclinical Studies
The purpose of this study is to culture primary human brain tumor cells with the specific aims of: 1. Develop primary cultures from human brain tumor surgical specimens 2.
- Trial name
- NCT01125826
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Albany Medical College
Brain and Central Nervous System Tumors
Pharmacologic Study of Methotrexate in Patients Undergoing Stereotactic Biopsy for Recurrent High-Grade Glioma
RATIONALE: Collecting fluid from a brain tumor using a small catheter may help doctors learn how much methotrexate gets into the tumor to kill the tumor cells.
- Trial name
- NCT00463008
- Testing
- methotrexate, pharmacological study
- Volunteers
- 12 people
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium
Impaired Cognition, Chemo-brain
Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer
This research study evaluates the effect of chemotherapy on cognition (thinking) and the brain in people with breast cancer.
- Conditions
- Impaired Cognition, Chemo-brain, Breast Cancer
- Trial name
- NCT02290834
- Testing
- Cognitive, functional and subjective assessments, MRI, PET Scan
- Where
- 2 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Tumor, Brain
Multimodal Connectome Study of Brain Tumor-operated Patients
In this pilot study, the investigators propose a multimodal evaluation of the brain connectivity of brain tumor patients, in order to better understand the effects induced by focal lesions on brain structure and function, as well…
- Trial name
- ConnecTC (NCT04163315)
- Testing
- dMRI, fMRI and electrocorticography
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Brain Tumors
Frailty as a Predictor of Neurosurgical Outcomes in Brain Tumor Patients
Frailty as an adjunct to preoperative assessment of neurosurgical patients has never been evaluated. This study aims to determine if frailty predicts neurosurgical complications in brain tumor patients and enhances current…
- Trial name
- NCT02530749
- Where
- United States
- Volunteers
- 265 people
- Sponsor
- University of Colorado, Denver
Glioblastoma, Glioblastoma Multiforme
Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas
This research is being done to find out if the study drug (ketoconazole) can enter brain tumors at a high enough amount to stop the tumor cells from dividing.
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain, Glioblastoma Multiforme, Adult
- Trial name
- NCT04869449
- Testing
- Ketoconazole
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Milton S. Hershey Medical Center
Brain and Central Nervous System Tumors
Iodine I 131 Monoclonal Antibody TNT-1/B in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody TNT-1/B (^131I MOAB TNT-1/B), can find tumor cells and carry tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00128635
- Testing
- iodine I 131 monoclonal antibody TNT-1/B
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.